Vigencell Q1 26: Op. loss 2.8B won, VT-EBV-N approval prep on track

Q1 2026 revenue 0.33B won (vs 0 in prior year), operating loss 2.84B won (vs 2.7B)
VT-EBV-N (NK/T-cell lymphoma) phase 2 completed, preparing for conditional approval (orphan drug in Korea and EU)
VC-302 (glioblastoma) and VC-420 (hepatocellular carcinoma) in preclinical, co-development with Terabest
Cash & short-term financial assets 31.45B won, debt ratio 22% - stable financials
Ongoing lawsuit with former executive for 1.28B won in severance claim